Differences in the treatment of coronary heart disease between countries as revealed in the Scandinavian Simvastatin Survival Study (4S)

2.50
Hdl Handle:
http://hdl.handle.net/2336/93623
Title:
Differences in the treatment of coronary heart disease between countries as revealed in the Scandinavian Simvastatin Survival Study (4S)
Authors:
Faergeman, O; Kjekshus, J; Cook, T; Pyörälä, K; Wilhelmsen, L; Thorgeirsson, G; Pedersen, T R
Citation:
Eur. Heart J. 1998, 19(10):1531-7
Issue Date:
1-Oct-1998
Abstract:
AIM: To assess differences in treatment of ischaemic heart disease in the Scandinavian countries. METHODS AND RESULTS: The Scandinavian Simvastatin Survival Study (4S) lasted 5.4 years and showed that death rates in 4444 patients with coronary heart disease were 30% lower in those treated with simvastatin to lower serum cholesterol than in those given placebo. Apart from this main result, the 4S provided detailed information on rates of death and other manifestations of coronary heart disease, as well as on use of non-lipid forms of therapy. There were substantial differences in 4S placebo group rates of mortality, coronary deaths and major coronary events between countries. Surgical and medical therapy varied importantly between countries. CONCLUSIONS: Major inter-country differences in rates of death and myocardial infarction in patients with coronary heart disease were likely to be due to a composite of differences in baseline characteristics including smoking. They occurred in a setting of very uneven exploitation of the potential for improving survival of patients with ischaemic heart disease.
Description:
To access publisher full text version of this article. Please click on the hyperlink in Additional Links field
Additional Links:
http://dx.doi.org/10.1053/euhj.1998.1191

Full metadata record

DC FieldValue Language
dc.contributor.authorFaergeman, Oen
dc.contributor.authorKjekshus, Jen
dc.contributor.authorCook, Ten
dc.contributor.authorPyörälä, Ken
dc.contributor.authorWilhelmsen, Len
dc.contributor.authorThorgeirsson, Gen
dc.contributor.authorPedersen, T Ren
dc.date.accessioned2010-03-04T12:58:47Z-
dc.date.available2010-03-04T12:58:47Z-
dc.date.issued1998-10-01-
dc.date.submitted2010-03-04-
dc.identifier.citationEur. Heart J. 1998, 19(10):1531-7en
dc.identifier.issn0195-668X-
dc.identifier.pmid9820992-
dc.identifier.doi10.1053/euhj.1998.1191-
dc.identifier.urihttp://hdl.handle.net/2336/93623-
dc.descriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links fielden
dc.description.abstractAIM: To assess differences in treatment of ischaemic heart disease in the Scandinavian countries. METHODS AND RESULTS: The Scandinavian Simvastatin Survival Study (4S) lasted 5.4 years and showed that death rates in 4444 patients with coronary heart disease were 30% lower in those treated with simvastatin to lower serum cholesterol than in those given placebo. Apart from this main result, the 4S provided detailed information on rates of death and other manifestations of coronary heart disease, as well as on use of non-lipid forms of therapy. There were substantial differences in 4S placebo group rates of mortality, coronary deaths and major coronary events between countries. Surgical and medical therapy varied importantly between countries. CONCLUSIONS: Major inter-country differences in rates of death and myocardial infarction in patients with coronary heart disease were likely to be due to a composite of differences in baseline characteristics including smoking. They occurred in a setting of very uneven exploitation of the potential for improving survival of patients with ischaemic heart disease.en
dc.language.isoenen
dc.publisherOxford University Pressen
dc.relation.urlhttp://dx.doi.org/10.1053/euhj.1998.1191en
dc.subject.meshAngiotensin-Converting Enzyme Inhibitorsen
dc.subject.meshAnticholesteremic Agentsen
dc.subject.meshAspirinen
dc.subject.meshCalcium Channel Blockersen
dc.subject.meshCause of Deathen
dc.subject.meshCoronary Diseaseen
dc.subject.meshFemaleen
dc.subject.meshFinlanden
dc.subject.meshFollow-Up Studiesen
dc.subject.meshHumansen
dc.subject.meshIcelanden
dc.subject.meshMaleen
dc.subject.meshMiddle Ageden
dc.subject.meshMyocardial Revascularizationen
dc.subject.meshPrognosisen
dc.subject.meshScandinaviaen
dc.subject.meshSimvastatinen
dc.subject.meshSurvival Rateen
dc.subject.meshWarfarinen
dc.titleDifferences in the treatment of coronary heart disease between countries as revealed in the Scandinavian Simvastatin Survival Study (4S)en
dc.typeArticleen
dc.contributor.departmentDepartment of Medicine and Cardiology, Aarhus Amtssygehus, Aarhus, Denmark.en
dc.identifier.journalEuropean heart journalen

Related articles on PubMed

All Items in Hirsla are protected by copyright, with all rights reserved, unless otherwise indicated.